For the full year 2026, Hyperfine expects revenue between $20 million to $22 million, representing year-over-year growth at the midpoint of 55%. Gross margin for 2026 is forecast in the range of 50% ...

Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality This major Swoop® system scanner redesign and ...

Hyperfine (HYPR) announced CE approval of its latest generation of AI-powered Swoop system software under the European Medical Device Regulation. This approval marks a step in positioning Hyperfine ...

A new multi-direction DWI sequence, the latest Swoop® system software, and the first advancement in Hyperfine’s Optive AI™ software, delivers clearer, higher-quality images for stroke diagnosis, ...

Hyperfine today announced that its FDA-cleared portable magnetic resonance (MR) brain imaging system, called the Swoop system, has gained CE approval for its latest generation of AI-powered software.

The U.S. FDA granted 510 (k) clearance to Hyperfine Inc. for improved artificial intelligence (AI)-powered software for its Swoop portable magnetic resonance imaging (MRI) device. The company launched ...

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic ...